Profound Medical to Release Fourth Quarter and Full Year 2025 Financial Results on March 5th – Conference Call to Follow

Core Insights - Profound Medical Corp. will announce its fourth quarter and full year 2025 financial results on March 5, 2026, followed by a conference call to discuss the results and business developments [1][2]. Company Overview - Profound Medical Corp. is a commercial-stage medical device company focused on developing and marketing innovative interventional MRI (iMRI) procedures [3]. Product Offerings - The company is commercializing TULSA-PRO, a technology that integrates real-time MRI, AI-enhanced planning, and robotically-driven ultrasound for treating prostate diseases. The TULSA Procedure is designed to preserve urinary continence and sexual function while effectively targeting prostate tissue [4]. - TULSA-PRO is CE marked, Health Canada approved, and has received 510(k) clearance from the U.S. FDA [4]. - Profound is also marketing Sonalleve, a therapeutic platform approved for treating uterine fibroids and other conditions. It has received CE marking and FDA approval under a Humanitarian Device Exemption for specific treatments [5].